31 Mar 2026
Morning Note – 31 March 2026
Allergy Therapeutics plc (AGY:LON), 9.5 | Duke Capital Limited (DUKE:LON), 25.2 | GETECH Group plc (GTC:LON), 2.0 | IXICO Plc (IXI:LON), 8.5 | Poolbeg Pharma PLC (POLB:LON), 4.8 | Plexus Holdings (POS:LON), 3.4 | RC Fornax plc (RCFX:LON), 7.6 | Shield Therapeutics Plc (STX:LON), 6.6 | Tekmar Group Plc (TGP:LON), 13.2 | Touchstone Exploration Inc (TXP:LON), 6.8 | Venture Life Group Plc (VLG:LON), 56.5
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
Morning Note – 31 March 2026
Allergy Therapeutics plc (AGY:LON), 9.5 | Duke Capital Limited (DUKE:LON), 25.2 | GETECH Group plc (GTC:LON), 2.0 | IXICO Plc (IXI:LON), 8.5 | Poolbeg Pharma PLC (POLB:LON), 4.8 | Plexus Holdings (POS:LON), 3.4 | RC Fornax plc (RCFX:LON), 7.6 | Shield Therapeutics Plc (STX:LON), 6.6 | Tekmar Group Plc (TGP:LON), 13.2 | Touchstone Exploration Inc (TXP:LON), 6.8 | Venture Life Group Plc (VLG:LON), 56.5
- Published:
31 Mar 2026 -
Author:
David Buxton | Ian McInally | Chris Donnellan | James McCormack | Andrew Renton | Adam McCarter | Mike Mitchell | James Midgley -
Pages:
18 -